Compile Data Set for Download or QSAR
Report error Found 355 of affinity data for UniProtKB/TrEMBL: P11532
TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645195(US11873290, Compound 27 | 2-((3-phenylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:Following example 15, the counter screen was done using frozen myofibril pellets obtained from cardiac tissue. The assay was done in the same manner ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645204(US11873290, Compound 38 | 2-((5-(pyridin-2-yl)- 1,...)
Affinity DataIC50: 1.00E+4nMAssay Description:Following example 15, the counter screen was done using frozen myofibril pellets obtained from cardiac tissue. The assay was done in the same manner ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645186(US11873290, Compound 17 | 6-(6- (difluoromethoxy)p...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645181(US11873290, Compound 12 | 2-(benzo[d]oxazol-2- ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645182(US11873290, Compound 13 | 2-((3-methylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645183(US11873290, Compound 14 | 6-(6- (difluoromethoxy)p...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645194(US11873290, Compound 26 | 2-((3- (difluoromethyl)...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645195(US11873290, Compound 27 | 2-((3-phenylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645196(US11873290, Compound 28 | 2-((5-fluoropyridin-3- y...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645190(US11873290, Compound 22 | 6-(6- (difluoromethoxy)p...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645170(US11873290, Compound 1 | 2-((5-chloropyridin-3- yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645171(US11873290, Compound 2 | 2-((5-chloropyridin-3- yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645172(US11873290, Compound 3 | 2-((6-chloropyridin-3- yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645177(US11873290, Compound 8 | 6-(2-(2,2,2- trifluoroet...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645178(US11873290, Compound 9 | 6-(6- (difluoromethoxy)py...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645256(US11873290, Compound 94 | 2-((5-phenyl-1,3,4- thia...)
Affinity DataIC50: 1.00E+4nMAssay Description:Following example 15, the counter screen was done using frozen myofibril pellets obtained from cardiac tissue. The assay was done in the same manner ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645180(US11873290, Compound 11 | 2-((5- chlorobenzo[d]oxa...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645173(US11873290, Compound 4 | 2-(pyridin-3-ylmethyl)- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645174(US11873290, Compound 5 | 2-((6- (difluoromethoxy)p...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645175(US11873290, Compound 6 | 2-((5-fluoropyridin-3- yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645176(US11873290, Compound 7 | 2-((6-methylpyridin-3- y...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645217(US11873290, Compound 52 | 2-((5-fluoro-6- methylpy...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645218(US11873290, Compound 53 | 2-(oxazol-5-ylmethyl)- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645219(US11873290, Compound 54 | 2-((5-fluoropyridin-3- y...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645220(US11873290, Compound 55 | 2-((5- fluorobenzo[d]ox...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645215(US11873290, Compound 50 | 2-((5-fluoropyridin-3- y...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645216(US11873290, Compound 51 | 5-((6-oxo-3-(2-(2,2,2- t...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645225(US11873290, Compound 60 | 2-((2-methyloxazol-5- yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645226(US11873290, Compound 61 | 2-((2-methylthiazol-5- y...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645227(US11873290, Compound 64 | 6-(2-(bicyclo[1.1.1]pent...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645228(US11873290, Compound 65 | 2-((3-methylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645221(US11873290, Compound 56 | 2-((3- (methoxymethyl)is...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645223(US11873290, Compound 58 | 2-((1-methyl-1H- pyrazol...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645224(US11873290, Compound 59 | 2-(thiazol-5-ylmethyl)- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645201(US11873290, Compound 34 | 2-((4-methylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645202(US11873290, Compound 36 | 2-((3-ethylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645203(US11873290, Compound 37 | ethyl 5-((6-oxo-3-(2- (2...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645204(US11873290, Compound 38 | 2-((5-(pyridin-2-yl)- 1,...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645197(US11873290, Compound 30 | 2-((3-(pyridin-2- yl)iso...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645198(US11873290, Compound 31 | 2-((3- cyclopropylisoxa...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645199(US11873290, Compound 32 | 5-((6-oxo-3-(2-(2,2,2- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645200(US11873290, Compound 33 | 2-((3-acetylisoxazol-5- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645205(US11873290, Compound 39 | 2-((4-methyl-3- phenylis...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645206(US11873290, Compound 40 | 2-((5-(pyridin-3-yl)- 1,...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645207(US11873290, Compound 41 | 2-((6-methylpyridazin- 3...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645250(US11873290, Compound 87 | 2-((5-chloro-6- methylp...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645251(US11873290, Compound 88 | 2-((3-(4-fluorophenyl)-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645252(US11873290, Compound 89 | 2-((3-phenyl-1,2,4-oxadi...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645257(US11873290, Compound 95 | 2-((5-(piperidin-1-yl)- ...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

TargetDystrophin(Human)
Edgewise Therapeutics

US Patent
LigandPNGBDBM645258(US11873290, Compound 96 | 2-((1H-indazol-5- yl)me...)
Affinity DataIC50: 1.00E+4nMAssay Description:BSA, ATP, NADH, PEP, and DTT solutions were thawed at room temperature, then transferred to ice. Pellet-frozen myofibrils (approximately twice the re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2024
Entry Details
US Patent

Displayed 1 to 50 (of 355 total ) | Next | Last >>
Jump to: